Rationale for update:
• Updated to refer to Alberta Health’s biological product pages for COVID-19 booster dose information.

Note: These recommendations do not impose mandatory immunization requirements on transplant candidates and recipients, and are not intended to replace the clinical skill, judgement and decisions of the individual’s transplant healthcare team. These recommendations are meant to supplement existing recommendations for routine immunization as outlined in the current Alberta Immunization Policy. See also Principles of Immunization for Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients.

Inactivated vaccines should be given at least 2 weeks before transplantation and live attenuated vaccines should be given at least 4 weeks prior to transplantation. Consult with an attending physician before providing live vaccines.¹

### 1. Routine Immunizations – Before Transplant

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Series</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COVID-19</strong></td>
<td>3 doses</td>
<td>Consult with primary health care provider or medical specialist prior to immunization, including timing of when vaccine should be given. mRNA vaccine is preferentially recommended except in the event of a contraindication. COVID-19 vaccines may be given simultaneously with other inactivated vaccines. A shortened interval no less than 28 days between dose 2 and dose 3 may be considered for those with increased risk of exposure and greater severity of immunodeficiency based on their clinician’s recommendation. Following completion of the primary series as outlined above, refer to Alberta Health’s COVID-19 biological product pages for current recommendations for additional doses or booster doses.</td>
</tr>
<tr>
<td><strong>dTap or Td</strong></td>
<td>3 doses</td>
<td>If an adult requires completion of a primary series of Td/dTap, dTap vaccine should be administered. Adults who have not previously received a dose of acellular pertussis in adulthood should receive a dose of Td, followed by dTap boosters every 10 years. <strong>Note:</strong> If both dTap and polio are indicated, dTap-IPV may be used.</td>
</tr>
<tr>
<td><strong>Polio IPV</strong></td>
<td>3 doses</td>
<td>Primary immunization with inactivated polio vaccine is recommended for all previously unimmunized SOT candidates and recipients.¹ <strong>Note:</strong> Booster doses of IPV are not necessary for adults living in Canada except for adults at an increased risk of exposure. Those at higher risk of exposure (e.g., health care workers and laboratory workers) may receive a single lifetime booster dose.¹ If both polio and dTap are indicated, dTap-IPV may be used. Immunity screening after immunization is not recommended.</td>
</tr>
<tr>
<td>Vaccine</td>
<td>Series</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>Pneu-C13 followed by Pneumo-P at least eight weeks later.</td>
<td>There should be at least eight weeks between Pneu-C13 and Pneumo-P&lt;sup&gt;1,2&lt;/sup&gt; Adults who have already received Pneumo-P should receive Pneu-C13. Pneu-C13 should be administered at least 1 year after any previously administered dose of Pneumo-P&lt;sup&gt;2,3&lt;/sup&gt; Immunity screening after immunization is not recommended.</td>
</tr>
<tr>
<td>Pneumo-P</td>
<td>1 re-immunization of Pneumo-P 5 years after the initial dose of Pneumo-P&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>1 dose</td>
<td>One dose is recommended for candidates/ recipients of SOT five years of age and older regardless of previous Hib immunization (at least one year after any previous dose)&lt;sup&gt;1&lt;/sup&gt; Immunity screening after immunization is not recommended.</td>
</tr>
<tr>
<td>MenC-ACYW</td>
<td>18 – 24 years of age*: One dose (unless received as an adolescent at 12 years of age or older.)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Recommended for individuals: 18 – 24 years of age inclusive Increased risk - 18 years of age and older as listed&lt;sup&gt;1&lt;/sup&gt;: Anatomical or functional asplenia including sickle cell disease HIV infection Congenital complement, properdin, factor D or primary antibody deficiencies Acquired complement deficiency e.g. those receiving eculizumab (Soliris™) Laboratory workers routinely exposed to <em>Neisseria meningitides</em> Note: Provincially funded vaccine is not provided for international travellers. Refer individuals to local travel health professionals. Immunity screening after immunization is not recommended.</td>
</tr>
<tr>
<td></td>
<td>*Booster doses are not indicated.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased risk: 18 years of age and older.**</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Underlying medical condition)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Two doses eight weeks apart</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**Booster dose every 5 years if risk continues.&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased risk of exposure (laboratory workers): One dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**Booster dose every 5 years if risk continues.&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>MenC-ACYW</td>
<td>18 – 24 years of age inclusive and those 25 years of age and older at higher risk)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Two doses eight weeks apart</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**Booster dose every 5 years if risk continues.&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased risk of exposure (laboratory workers): One dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**Booster dose every 5 years if risk continues.&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Follow the dosage and schedule for hypo-responsive individuals for Hepatitis B Vaccine.</td>
<td>Follow the dosage and schedule for hypo-responsive individuals for Hepatitis B Vaccine.</td>
</tr>
<tr>
<td>HBVD&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Follow the dosage and schedule for hypo-responsive individuals for Hepatitis B Vaccine.</td>
<td>Laboratory Recommendations Screen for anti-HBs within 1 – 6 months after the series is completed. If antibody levels are less than 10 IU/L, repeat the series once and retest for anti-HBs within 1 – 6 months after the repeat series.&lt;sup&gt;1&lt;/sup&gt; Periodic screening as recommended by the transplant physician taking into account the severity of the immunocompromised state and whether or not the risk of hepatitis B is still present.&lt;sup&gt;1&lt;/sup&gt; Ordering serology and interpretation of the results is the responsibility of the transplant physician.</td>
</tr>
<tr>
<td>Vaccine</td>
<td>Series</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| **Hepatitis A HAV**      | Two doses: Second dose 6 – 12 months after the first dose. | Only for those considered at high risk:  
- Lifestyle risks of infection, including people engaging in illicit drug use (injectable and non-injectable) and men having sex with men  
- Chronic liver disease and liver transplantation  
- Individuals receiving repeated replacement of plasma-derived clotting factors.  
- Workers involved in hepatitis A virus research or production of hepatitis A vaccine who may be exposed to hepatitis A virus.  
- Zoo-keepers, veterinarians and researchers who handle non-human primates.  
- Household /close contacts of children adopted from hepatitis A endemic countries.  
- Populations/communities at risk of hepatitis A outbreaks or in which hepatitis A is highly endemic.  
**Note:** Provincially funded vaccine is not provided for travellers – refer individuals to local travel health professionals. Immunity screening after HAV immunization is not routinely recommended.1 |
| **Human Papillomavirus Vaccine HPV** (18 – 26 years of age inclusive2) | Three doses administered at 0, 2 and 6 months1 | Immunity screening after immunization is not recommended.                                                                                                                                                  |
| **INFLUENZA (inactivated)** | Annually | Administer a dose of inactivated influenza vaccine annually. Influenza vaccine can be administered as early as three months post-transplant.  
- Solid organ transplant recipients: Live attenuated influenza vaccine (LAIV) is contraindicated.  
- Household contacts: Immunize annually with either inactivated influenza vaccine or live attenuated influenza vaccine.  
Immunity screening after immunization is not recommended. |
| **MMR (only susceptible adults* pre-transplant)**1 | One or two doses.  
If a second dose is indicated the interval between doses should be at least four weeks.1 (See Laboratory Recommendations) | MMR is to be administered a minimum of four weeks prior to transplant.1  
**Not recommended post-transplantation**  
*Evidence of Measles Immunity:*  
- Individuals born in 1970 or later  
  ➢ with a documented history of two doses of measles-containing vaccine OR  
  ➢ history of laboratory confirmed measles disease OR  
  ➢ laboratory evidence of measles immunity.  
- Individuals born prior to 1970 are generally considered to be immune. Serology may be recommended by the transplant physician.  
**Laboratory Recommendations**  
- Screen for measles and rubella immunity (IgG) one month after the first dose of vaccine.  
- If non-immune and a second dose can be administered, provide a second dose (after consult with the transplant physician) and repeat screening in one month. |
## Vaccine Series

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Series</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **Varicella (chickenpox)***   | 1 or 2 doses | • If seroconversion for measles, or rubella has been demonstrated following a dose of MMR, a second dose is not required. However, it is recommended to provide age appropriate MMR if time allows pre-transplant.  
  • Annual screening for immunity is not recommended.  
  Ordering serology and interpretation of the results is the responsibility of the transplant physician. |
| Varicella Vaccine (only susceptible adults* pre-transplant) | 1 or 2 doses | *Evidence of Immunity:  
  • history of two doses of varicella vaccine after 12 months of age OR  
  • laboratory evidence of immunity  
  Varicella vaccine is to be administered a minimum of four weeks prior to transplantation, and at least 8 weeks before receiving Shingrix® (if applicable).2,4,6  
  **Not recommended post-transplantation**  
  **Laboratory Recommendations**  
  • Routine screen pre-transplant includes varicella IgG testing to confirm disease history.  
  • Serology is recommended one month after one dose of varicella vaccine and if seroconversion is demonstrated consider immune (a second dose is not required). However, it is recommended to provide a second dose of varicella vaccine if time allows pre-transplant.  
  • If non-immune to provide a second dose of varicella vaccine if time allows pre-transplant.  
  Ordering serology and interpretation of the results is the responsibility of the transplant physician. |
| **Herpes-Zoster (Shingles) Vaccine** | Adults 18 years of age and older.* | Shingrix® (non-live recombinant Herpes Zoster vaccine)  
  Shingrix® is recommended for adult SOT by transplant physicians for those 18 years of age and older.1,4 This includes individuals who have received Zostavax® prior to transplant. An interval of one year is recommended between live attenuated Herpes Zoster vaccine (Zostavax®) and Shingrix®.  
  Vaccine should be provided at least 2 weeks prior to transplant as with other inactivated vaccines.4  
  If an individual received varicella vaccine recently, there is to be a minimum of 8 week spacing before Shingrix® can be administered6,7.  
  Post-transplant immunization may resume once the individual is on baseline immunosuppression, usually 6 to 12 months after transplant, and as determined appropriate by the individual’s attending transplant physician.1,4  
  Immunity screening after immunization is not recommended.  
  Shingrix® is available through the provincially funded immunization program. |

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8
---|---|---|---|---|---|---|---

*Evidence of Immunity:  
• history of two doses of varicella vaccine after 12 months of age OR  
• laboratory evidence of immunity
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Series</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults 50 years of age and older</td>
<td>Zostavax® (live attenuated Herpes Zoster vaccine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If Shingrix® is contraindicated, Zostavax® may be considered pre-transplant for individuals with no contraindications to the use of live vaccines and if the vaccine can be administered four weeks or more prior to the transplant.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Individuals should discuss the vaccine with their transplant physician. Zostavax® is not available through the provincially funded immunization program. It is available by prescription and may be purchased and administered at local pharmacies.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Zostavax® is contraindicated post-transplant.</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunity screening after immunization is not recommended.</td>
<td></td>
</tr>
</tbody>
</table>
1. Non-routine Immunizations – Before and/or After Transplant

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Series (if needed)</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **Hepatitis A**  | Two doses: Second dose 6 – 12 months after the first dose.                        | Only for those considered at high risk:  
- Lifestyle risks of infection, including people engaging in illicit drug use (injectable and non-injectable) and men having sex with men  
- Chronic liver disease, liver transplantation; chronic liver GVHD following HSCT  
- Individuals receiving repeated replacement of plasma-derived clotting factors.  
- Workers involved in hepatitis A virus research or production of hepatitis A vaccine who may be exposed to hepatitis A virus.  
- Zoo-keepers, veterinarians and researchers who handle non-human primates.  
- Household /close contacts of children adopted from hepatitis A endemic countries.  
- Populations/communities at risk of hepatitis A outbreaks or in which hepatitis A is highly endemic.  
**Note:**: Provincially funded vaccine is not provided for travellers – refer individuals to local travel health professionals.  
Immunity screening after HAV immunization is not routinely recommended.

| **Rabies**       | Pre-exposure: days 0, 7, 21 or 28  
Post-exposure: Rabies Immune Globulin and vaccine on day 0, and vaccine only on days 3, 7, 14 and 28.  
(Require 5 dose post-exposure series.)  
Serology every two years if pre-exposure risk continues.  
Booster as indicated depending upon serology results. | Pre-exposure: Should be administered intramuscularly only to those considered high risk (e.g. veterinary health technicians).  
Should be administered pre-transplant if possible, and completed at least 14 days before starting immunosuppressants.  
Post-exposure: Rabies prophylaxis can be administered intramuscularly at any time before or after transplantation if indicated.  
**Laboratory Recommendations**  
Pre-exposure: Immunity screening is recommended 7 – 14 days after last dose of the series.  
Post-exposure: Immunity screening is recommended 7 – 14 days after the completion of the vaccine series.  
If an acceptable antibody response is not obtained, revaccination with a second rabies vaccine series is recommended, followed by further serologic testing.  
**Ordering serology and interpretation of the results is the responsibility of the transplant physician.**

| **Typhoid Fever** | 1 dose  
Booster every three years if at continued high risk. | *Only for those considered high risk. Individuals at high risk include household and/or intimate contacts of a typhoid carrier and laboratory workers who manipulate *Salmonella typhi*.  
Immunity screening after immunization is not recommended.  

2. Ongoing Recommendations after Transplant

**Note:** Immunization may resume once the individual is on baseline immunosuppression, usually 6 to 12 months after transplant,1 and as determined appropriate by the individual’s attending transplant physician. If immunizations were not completed prior to transplant, complete the series for inactivated vaccines, including COVID-19 immunization, as previously indicated.

**Live vaccines, are contraindicated after transplant.**
References


